
UniQure N.V. (NASDAQ:QURE) shares are trading higher Wednesday after the company announced positive topline results from Phase I/II study of AMT-130 in patients with Huntington’s Disease.
What To Know: The study met its primary endpoint, with high-dose AMT-130 showing a statistically significant 75% slowing of disease progression at 36 months as measured by cUHDRS compared to an external control. The therapy also achieved a key secondary endpoint, demonstrating a statistically significant 60% slowing of disease progression as measured by Total Functional Capacity.